Betagistin-SZ, 16 mg, 60 pcs

the active substance is betahistine dihydrochloride.

Excipients:

microcrystalline cellulose;

lactose (milk sugar);

lemon acid;

colloidal silicon dioxide (aerosil);

talc;

magnesium stearate;

sodium lauryl sulfate;

starch 1500 (pregelatinized starch).

Description:

16 mg tablets - white or almost white in color, flat-cylindrical in shape, with chamfer and risk.

Pharmacotherapeutic group:

histamine drug.

ATX Code: [N07CA01]. 

Pharmacodynamics: 

Betagistin acts mainly on the histamine H1 and H3 receptors of the inner ear and vestibular nuclei of the central nervous system. By direct agonistic action on the H1 receptors of the vessels of the inner ear, as well as indirectly through the action on the H3 receptors, it improves microcirculation and capillary permeability, normalizes the pressure of the endolymph in the labyrinth and cochlea. However, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of the H3 receptors of the nuclei of the vestibular nerve. It improves the conductivity in the neurons of the vestibular nuclei at the level of the brain stem. A clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and hearing improvement if it decreases. 

Pharmacokinetics: 

It is absorbed quickly, communication with plasma proteins is low. The maximum concentration in plasma after 3 hours. The elimination half-life in 3-4 hours. It is almost completely excreted by the kidneys in the form of a metabolite (2-peridylacetic acid) within 24 hours.

• treatment and prevention of vestibular dizziness of various origins;
• syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
• Meniere's disease or syndrome.

- Hypersensitivity to any of the components of the drug, children under 18 years of age (due to lack of data), pregnancy and lactation (due to lack of data);

With caution: peptic ulcer of the stomach or duodenum (including history), pheochromocytoma, bronchial asthma. These patients should be regularly observed during treatment;

- pregnancy and lactation.

There is not enough data to assess the effects of the drug during pregnancy and lactation. In this regard, it is not recommended to take during pregnancy. At the time of treatment, it is necessary to stop breastfeeding.

Inside, while eating. 1 / 2-1 tablets 3 times / day.

Improvement is usually noted already at the beginning of therapy.

A stable therapeutic effect occurs after two weeks of treatment and can increase over several months of treatment.

The treatment is long. The duration of the drug is selected individually.

Symptoms: nausea, vomiting, cramps.

Treatment: gastric lavage, intake of activated carbon, symptomatic therapy. 

Pills